Discover insights from the Phase 3 LEAP-012 study evaluating lenvatinib + pembrolizumab + TACE versus double placebo + TACE for patients with intermediate HCC.

 

In this short expert video, Prof. Arndt Vogel covers the key findings from the publication and places the results into clinical context.

 

Watch the video for key takeaways and download the infographic for a quick reference.

 

See the publication in The Lancet: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract

 

Clinical takeaways

  • LEAP-012 further supports the approach of combining locoregional therapies with IO-based therapies
  • Locoregional therapies combined with IO-based therapies should be more frequently considered in clinical practice, particularly for patients with intermediate HCC, as a potential strategy to downstage or downsize the disease
  • Future directions include additional data on overall survival and quality of life, to further define the long-term benefits and clinical applicability
  • Know the latest data of the multimodal approach for intermediate HCC, combining systemic treatment with TACE
  • Be able to place the LEAP-012 results into clinical context, in order to make informed treatment decisions

Prof. Vogel is a clinician scientist at the rank of a full professor at the University of Toronto, Canada. He is appointed as the Longo Family Chair in Liver Cancer Research and is leading a multi-pronged research program in basic and clinical science at the Toronto General Hospital and the Princess Margarete Cancer Center. Before joining UNH, he worked as senior consultant at Hannover Medical School for more than 20 years and still holds a research position there. 

Prof. Vogel’s scientific focus is the translational and clinical research in gastrointestinal cancer. Since 2004, he is leading a translational research group interested in the pathogenesis of hepatobiliary cancers and in precision medicine. Arndt Vogel is a clinical investigator in oncology since 2006 and has served as principal investigator on numerous clinical trials. He is author or co-author of more than 330 articles published in peer-reviewed journals including Lancet, Lancet Oncology, Cancer Cell, and Gastroenterology among others. 

Prof. Vogel is member of societies including ESMO, ASCO, and EASL. He is member and chairman of Hepatobiliary Cancer Study Group of the AIO, a collaborative group in clinical oncology in Germany. Within ESMO, he is member of the ESMO Guidelines Steering Committee. He has responsibilities in the establishment of the national guideline and is the coordinator of the ESMO clinical practice guideline on the management of hepatocellular carcinoma and biliary tract cancer.   

Prof. Arndt Vogel has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Consultancy and advisory role: Roche, AstraZenca, Böhringer-Ingelheim, Ipsen, Incyte, Cogent, EISAI, Zymeworks, Biologix, BMS, Terumo, Elevar, Servier, MSD, Tahio, Jazz Pharma, Medivir, Abbvie, Tyra, Falk, Janssen, Lilly 

Programme summary
Watch the video now
Share this programme
This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this programme.
Supporter Acknowledgement
This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this programme.
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre Laboratories.  

Meet the experts Independent IME approved

Other programmes of interest

video Video
Oncology 
The patient perspective: Living with NSCLC driven by a rare alteration

What to know, what to expect, and where to find support

Experts
Marcia Horn
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
BRAF Bombers PD-L1 Amplifieds MET crusaders
  • clock 8 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim.
animated-video Animated Video
Oncology 
Chemotherapy strategies for metastatic pancreatic ductal adenocarcinoma

Optimising 1st and 2nd line treatment

Experts
Prof. Eileen O'Reilly, Prof. Efrat Dotan
Endorsed by
ICAN international cancer advocacy network DiCE PanCAN
National Pancreas Foundation
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Ipsen USA.
podcast Podcast
Oncology 
HR+/HER2- metastatic breast cancer: Best practices in molecular testing and targeted therapy

Optimising precision medicine for improved patient outcomes

Experts
Dr Roberto Salgado, Assoc. Clinical Professor Rena Callahan
Endorsed by
ICAN international cancer advocacy network ISLB Exon20group
Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Mar 2025

Educational programme supported by an Independent Educational Grant from Thermo Fisher Scientific.
conference-update Conference update
Oncology 
Current and future treatment strategies for patients with ER+/HER2- early breast cancer

A closer look at the evolving treatment landscape

Experts
Prof. Michael Gnant, Prof. Giuseppe Curigliano
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Mar 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
podcast Podcast
Oncology 
ER+ metastatic breast cancer: Key insights on elacestrant from the latest EMERALD subgroup analyses

Experts' insights on treatment strategies in ER+ metastatic breast cancer settings

Experts
Dr Aditya Bardia, Dr Virginia Kaklamani
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Mar 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
eks
Experts Knowledge Share Video
Oncology 
HER2 testing: The evolving role of immunohistochemistry (IHC)

Best practices and interpretation of results in lung and ovarian cancer 

Experts
Prof. Fernando López-Ríos, MD, PhD, Prof. Christian Rolfo, Prof. Charlie Gourley
Endorsed by
Exon20group ICAN international cancer advocacy network Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 77 MIN
  • calendar Mar 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca.